Monoclonal Antibody to Complement component 1 Q subcomponent-binding protein, mitochondrial (C1QBP)
| Code | Size | Price |
|---|
| MAA651Hu21-20ul | 20ul | £87.00 |
Quantity:
| MAA651Hu21-100ul | 100ul | £162.00 |
Quantity:
| MAA651Hu21-200ul | 200ul | £218.00 |
Quantity:
| MAA651Hu21-1ml | 1ml | £499.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
HABP1; GC1QBP; SF2p32; GC1Q-R; GC1qR; P32; Hyaluronan Binding Protein 1; Splicing Factor SF2-Associated Protein; ASF/SF2-associated p32
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Complement component 1 Q subcomponent-binding protein, mitochondrial
Potency (Clone Number):
E2
Source:
Monoclonal antibody preparation
Usage:
Western blottin:g: 0.5-3ug/mL;
Immunohistochemistry: 5-30ug/mL;
Immunocytochemistry: 5-30ug/mL;
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-30ug/mL;
Immunocytochemistry: 5-30ug/mL;
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Hyaluronan Binding Protein 1 (HABP1) | RPA651Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||